
    
      The drug being tested in this study is called brigatinib (AP26113). Brigatinib is being
      tested to treat people who have anaplastic lymphoma kinase-positive (ALK+), advanced
      non-small-cell lung cancer (NSCLC).

      The study will enroll approximately 103 patients. Participants will be assigned to the
      treatment group:

      â€¢ Brigatinib

      All participants will be asked to take brigatinib 90 mg tablet in lead-in period for 7 days,
      followed by brigatinib 180 mg at the same time each day throughout the study.

      This multicenter trial will be conducted worldwide. The overall time to participate in this
      study is approximately 5 years. Participants will make multiple visits to the clinic, and 30
      days after last dose of study drug for a follow-up assessment.
    
  